WO2003028716A1 - Aqueous ecabet sodium solution preparation - Google Patents
Aqueous ecabet sodium solution preparation Download PDFInfo
- Publication number
- WO2003028716A1 WO2003028716A1 PCT/JP2002/009847 JP0209847W WO03028716A1 WO 2003028716 A1 WO2003028716 A1 WO 2003028716A1 JP 0209847 W JP0209847 W JP 0209847W WO 03028716 A1 WO03028716 A1 WO 03028716A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aqueous solution
- solution preparation
- acid
- preparation according
- sodium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- Hydrate Chemical name: (+)-(lR, 4aS, 10aR)-1,2,3,4,4a, 9,10,10a—Octahydro-1,4a Sulfodehydroabietic acid or its salt, which is a form that exists in an aqueous solution of —dimethyl-17- (1-methylethyl) -16-sulfo-11-phenanthrene, sulfonic acid 6-sodium salt pentahydrate).
- the present invention relates to an aqueous solution preparation which is stable, has little irritation and is easy to administer. Background art
- Inflammatory bowel disease refers to inflammatory diseases of the large intestine and small intestine caused by various intractable etiologies, mainly ulcers that are diffuse nonspecific inflammation of unknown cause that mainly invades the colonic mucosa and forms erosions and ulcers It includes colitis, Crohn's disease, a nonspecific granulomatous inflammatory disease with unexplained delicate or ulcers, and the intestinal tract in Bechett's disease, a chronic systemic inflammatory disease. Lesions are also included.
- the sulfodehydroabietic acid or a pharmacologically acceptable salt thereof represented by is developed, and this compound has an acid and pepsin secretion inhibitory action, etc., and prevents peptic ulcer (gastric ulcer, duodenal ulcer) or gastritis. It is useful as a therapeutic agent (JP-A-58-77814, JP-A-63-165361, JP-A-2-167258) or a prophylactic / therapeutic agent for dry eye and the like (Japanese Patent Application Laid-Open No. 9-1136832) is known. Recently, it has been found that this compound has an excellent effect on the prevention and treatment of inflammatory bowel disease (WO 01/34143 pamphlet). '
- sodium phosphate or sodium dihydrogen phosphate is blended, and the pH is adjusted to 5-7.
- An aqueous solution containing 0.05% or 0.5% W / V% of sodium (tonadium) is used.
- a solid preparation containing sodium beet is crushed and suspended in water. A cloudy one is used. Disclosure of the invention
- aqueous solution containing a relatively high concentration of vitreous sodium it is preferable to use an aqueous solution containing a relatively high concentration of vitreous sodium, but maintain the pH close to the body fluid to reduce irritation to the site of inflammation.
- water solubility is low at pH less than 7, and its water solubility changes greatly with temperature change.Therefore, it is stable if high concentration of water is dissolved without proper pH adjustment. It has been found that it is difficult to obtain an aqueous preparation.
- the present inventors have solved the above-mentioned problems, and have proposed an aqueous solution of sodium hydroxide.
- Various studies were carried out to obtain a stable aqueous drug formulation containing sulfodehydroabietic acid or its salt ion, which is stable and has little irritation to the site of inflammation when administered.
- p is selected from polycarboxylic acid salts and polyphosphoric acid salts while containing sulfodehydroabietic acid or a salt thereof at a ratio of I WZVO / O or more in terms of sodium hydroxide.
- Aqueous solution of vietnam sodium that contains at least one H buffer and an inorganic base and is adjusted to have a pH of 7 to 8.5 is suitable for the treatment of inflammatory bowel disease. They found that they could be used and completed the present invention.
- FIG. 1 is a sectional view showing a flexible container for enema.
- FIG. 2 is a sectional view showing another flexible container for enema.
- the concentration of sulfodehydroabietic acid or its salt ion which is a form present in the aqueous solution of vitreous sodium, is high, but the temperature change, It does not cause the precipitation of the crystal of iron hydroxide due to the generation of a local concentration gradient.
- the pH is close to that of body fluids, the pH change during storage is small, and the concentration of sulfodehydroabietic acid or its salt is high, but the osmotic pressure due to pH adjustment and stabilization Since the rise is suppressed and the aqueous solution can be made to be near isotonic, there is little irritation to the inflammatory site at the time of administration.
- the aqueous solution preparation of the present invention contains sulfodehydroabietic acid or a salt thereof at a concentration of 1 W / V% or more in terms of sodium hydroxide and contains ions, and contains a salt of polycarboxylic acid and a salt of polyphosphoric acid.
- One or more pH buffers selected from the following salts and an inorganic base are blended, and 1> ⁇ 1 is adjusted to a range of 7 to 8.5.
- Sulfodehydroabietic acid and the like are known, for example, JP-A-58-77814, JP-A-63-165361, JP-A-2-1677258 It can be produced by the method described in the publication or a method analogous thereto.
- the concentration of sulfodehydroabietic acid or a salt thereof is 1 W / V% or more, preferably 1 to 5 WZV%, more preferably 2 to 4 WZV% in terms of ethanol. .
- the aqueous solution preparation In the aqueous solution preparation, the water molecules contained in sodium hydroxide are taken up by water as a solvent, and the compound itself is also a sulfodehydroabietic acid monosodium salt and a sulfodehydroabietic acid monophenate. Although dianion and the like coexist, they do not exist in the state of sodium hydroxide, but the content in the 7-solution is indicated by the content as sodium sodium.
- the aqueous solution preparation of the present invention is not limited to a solution in which sodium hydroxide is dissolved in an aqueous medium, and an aqueous solution formulation having the same composition as that in which sodium sodium is dissolved is dissolved in a seven-medium medium.
- aqueous solution preparation of the present invention It is included in the aqueous solution preparation of the present invention irrespective of the type of the component.
- free sulfodehydroabietic acid is added to an aqueous solution containing natrimion to obtain the same composition as the aqueous solution preparation of the present invention.
- Formulations are also included in the aqueous solution formulations of the present invention.
- the salt of a polycarboxylic acid used as a pH buffer in the preparation of the present invention means a salt of an organic acid having a plurality of carboxyl groups in one molecule.
- the organic acid include malonic acid, Saturated or unsaturated dicarboxylic acids such as succinic acid, malic acid, fumaric acid, maleic acid, tartaric acid, mesaconic acid, and dartaric acid; and tricarboxylic acids such as citric acid.
- Examples of such polycarboxylic acid salts include alkali metal salts such as sodium salt and potassium salt.
- Preferred salts of polycarboxylic acids include sodium malate, sodium fumarate, sodium maleate, sodium tartrate, sodium citrate, and most preferably trisodium citrate.
- the salt of polyphosphoric acid used as a p H buffers of the present ⁇ formulation the general formula: (P n 0 3n + i ) (n + 2) ": linear represented by (n 2 or more integer)
- a salt composed of a condensed phosphoric acid anion and a conjugated cation for example, a salt of a diphosphate, triphosphate or tetraphosphate anion with an alkali metal ion (eg, sodium ion, potassium ion).
- Preferred salts of polyphosphoric acid include alkali metal salts of diphosphate, triphosphate or tetraphosphate, and particularly preferred is sodium salt of triphosphate.
- pH buffer IJs are blended in a range of 0.01 to 2 W / V%, preferably 0.01 to 1.5 W / V%, but in the case of polycarboxylic acid salts, 0.5 to 1.5 W / V%, In the case of a polyphosphoric acid salt, it is preferred to be blended in the range of 0.01 to 0.5 W / V%.
- Examples of the inorganic base used in the preparation of the present invention include alkali metal hydroxides such as sodium heptaoxide and hydroxide hydroxide, and alkali metal hydroxides such as calcium hydroxide and magnesium hydroxide. Sodium oxide is preferred.
- the inorganic base is added in an amount required to bring the pH of the 7-solution formulation to a range of 7-8.5, preferably 7.2-8.2.
- the addition is carried out by adding or dissolving the other components to the zk-based medium, and then adding an aqueous solution of an inorganic base with stirring while monitoring the H of the aqueous solution preparation with a pH meter.
- L0WZV% preferably 1 to 1
- the method for preparing the aqueous solution preparation of the present invention is not particularly limited, and a predetermined amount of sodium hydrate is added or dissolved in an aqueous medium (for example, distilled water for injection or purified water) with heating. To the mixture is added a predetermined amount of pH buffer and, if desired, the following other additives, and then an inorganic base: Adjust H to a range of 7-8.5 to make a stable solution.
- an aqueous medium for example, distilled water for injection or purified water
- sodium ecabet, 1> ⁇ 1 buffer, and other additives are simultaneously added to an aqueous medium or dissolved by heating, and then the pH is adjusted with an inorganic base to obtain a stable solution. Can be done.
- the aqueous solution preparation of the present invention may optionally contain a preservative, a thickening agent, a solubilizing agent, a tonicity agent, and the like.
- the preservative is added to suppress the growth of various bacteria during storage of the aqueous solution preparation, but is preferably nonionic so as not to greatly affect the osmotic pressure of the aqueous solution.
- Lower phenolic esters of p-hydroxybenzoic acid that can effectively suppress reproduction metalhinoleestenole, ethinoleestenole, propinoleestenole, petitnole) Ester
- dehydroacetic acid and the like can be used.
- Preferred preservatives include methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, propyl p-hydroxybenzoate and the like. If necessary, two or more of these preservatives may be mixed. You may use it.
- the amount of these preservatives is usually in the range of 0.05 to 0.2 W / V%, preferably 0.07 to 0.15 W / V%.
- the viscous agent is added to add viscosity to the aqueous solution preparation of the present invention so that the aqueous solution preparation can easily stay near the affected part when the solution preparation of the present invention is intestinal-administered.
- xanthan gum Rhone Poulin
- carboxymethylcellulose sodium salt eg, carboxymethylcellulose sodium manufactured by Daicel Chemical Industries, Ltd.
- solubilizer examples include polyethylene glycol (polyethylene glycol manufactured by Katayama Chemical Co., Ltd., Macguchi Gall manufactured by NOF Corporation), sucrose fatty acid ester (such as Ryoto Sugar Ester manufactured by Mitsubishi Kasei), and polyoxyethylene polyoxypropylene glycol.
- a water-soluble inorganic base such as sodium chloride and a saccharide such as D-mannitol can be used as appropriate.
- the aqueous solution preparation of the present invention is particularly useful for the prevention and / or treatment of inflammatory bowel disease.
- Inflammatory bowel disease is not limited to inflammatory bowel disease in a narrow sense, such as Crohn's disease and ulcerative colitis. It refers to a broad range of inflammatory bowel diseases, including hematologic enteritis, drug-induced colitis, radioactive enteritis, and infectious enteritis.
- prevention refers to the improvement of symptoms, prevention of severe symptoms, maintenance of remission, prevention of relapse, prevention of gastrointestinal stenosis, and prevention of recurrence after surgery.
- enema administration is preferable, and for example, a method such as rectum to sigmoid colon administration, or direct administration from a colostomy to the intestine is employed.
- the dosage varies depending on the method of administration, the age, weight, and condition of the patient, and the disease to be treated, but the preferred daily dose for an adult is usually from 10 to 100 mg / kg in terms of sodium sodium. 3 0 O m g kg body weight, more preferably in the range of 2 0 ⁇ 1 5 O mg / kg body weight.
- aqueous solution preparation of the present invention is sterilized by filtering with a membrane filter before filling the container, and filling the container, and then heating the container as necessary. Processing can be performed.
- the aqueous solution preparation of the present invention can be filled into a rigid container (eg, a glass container, a plastic bottle, etc.) and administered at the time of use using an enema device (eg, an enema).
- a rigid container eg, a glass container, a plastic bottle, etc.
- an enema device eg, an enema
- it can be filled into a flexible container suitable for enema administration, and can be administered enema directly from the container.
- a container body portion for filling the aqueous solution preparation of the present invention and an enema nozzle portion (having a backflow prevention function, etc.
- the material of the flexible container main body suitable for enema administration is a thermoplastic resin having a certain degree of heat resistance (for example, low-density polyethylene, high-density polyethylene, polypropylene, polymethinolebutene, poly- ene).
- the aluminum intermediate layer is made of a polymer such as polyethylene, polypropylene, nylon, ethylene copolymer, polystyrene, cellophane, etc.
- a film laminated with a sheet, or a polymer sheet such as polyethylene, polypropylene, nylon, or ethylene-bulcohol copolymer with aluminum vapor-deposited, or light-shielded to finolem or polyethylene, polypropylene, nylon, ethylene-vinyl alcohol copolymer, etc.
- the outer packaging may be performed with a light-shielding film such as a film formed by kneading the agent.
- Example 1 aqueous solution preparation of the present invention and its effects will be further described with reference to Examples and Experimental Examples. Although specifically described, the present invention is not limited to these.
- Example 1
- Example 5 Sodium hydroxide (2 g), methyl p-hydroxybenzoate (0.1 g), propyl p-hydroxybenzoate (0.02 g) and sodium sodium citrate (1 g) in purified water (8 Oml) It was heated and dissolved. This aqueous solution was adjusted to pH 7.4 with an aqueous solution of sodium hydroxide, and purified water was added thereto to add an aqueous solution of sodium hydroxide (100m2). 1) was prepared.
- Example 5 Sodium hydroxide (2 g), methyl p-hydroxybenzoate (0.1 g), propyl p-hydroxybenzoate (0.02 g) and sodium sodium citrate (1 g) in purified water (8 Oml) It was heated and dissolved. This aqueous solution was adjusted to pH 7.4 with an aqueous solution of sodium hydroxide, and purified water was added thereto to add an aqueous solution of sodium hydroxide (100m2). 1) was prepared.
- Example 5 Example 5
- Methyl p-hydroxybenzoate (0.1 g), xanthan gum (0.175 g, Mouth-Pouleun Rodigel 200, average molecular weight: 2,000,000) was added to polyethylene glycol (1.5 g, Katayama Chemical polyethylene glycol 400). , Average molecular weight: 400).
- sodium hydroxide (4 g) and sodium triphosphate (0.2 g) were added to purified water (8 Oml).
- a polyethylene glycol solution was added to the mixture under stirring, the pH was adjusted to 8 with an aqueous sodium hydroxide solution, and purified water was further added to prepare an aqueous sodium hydroxide solution (100 ml).
- Butyl p-hydroxybenzoate (0.005 g) and sodium carboxymethylcellulose sodium salt (1.4 g, carboxymethylcellulose sodium 1260 manufactured by Daicel Chemical Industries, average degree of etherification: 0.91) were combined with polyethylene glycol (1. 5 g, dissolved in Katayama Chemical's polyethylene glycol 400, average molecular weight: 400). Meanwhile, sodium hydroxide (4 g) and sodium triphosphate (0.2 g) were added to purified water (80 ml). A polyethylene glycol solution was added to the mixture with stirring, and then the pH was adjusted to 8 with an aqueous sodium hydroxide solution, and purified water was further added to prepare an aqueous solution of ethanol (100 ml).
- the aqueous solution of sodium hydroxide obtained in Example 1-8 can be used, for example, by filling a flexible container as shown in FIG. 1 or FIG. Comparative example
- Two sets of the aqueous solutions of Examples 1 and 2 and the comparative example filled in glass sample bottles were prepared. One set was stored at 60 ° C for one week and the other set was stored at 5 ° C for one month.
- aeruginosa (ATCC 9027) was suspended at a concentration of 10 7 to 10 8 ⁇ / ⁇ 1 to prepare a bacterial suspension. 1 ml of the bacterial suspension was inoculated into a sample bottle filled with the above aqueous solution, mixed, and stored in a thermostat at 25 ° C.
- the aqueous sodium salt solution of the present invention may be prepared by adding a specific pH buffer and adjusting the pH to a range of 7 to 8.5 with an inorganic base to obtain sulfodehydroabietic acid or Despite its high concentration of salt ions, it can be stored stably for a long period of time, and can exert the desired preventive and therapeutic effects on inflammatory bowel disease.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003532049A JP4044902B2 (ja) | 2001-09-27 | 2002-09-25 | エカベトナトリウム水性溶液製剤 |
EP02770213A EP1430892A4 (en) | 2001-09-27 | 2002-09-25 | PREPARATION OF AQUEOUS ECABET SODIUM SOLUTION |
US10/489,827 US20040259905A1 (en) | 2001-09-27 | 2002-09-25 | Aqueous ecabet sodium solution preparation |
MXPA04002868A MXPA04002868A (es) | 2001-09-27 | 2002-09-25 | Preparacion de solucion acuosa de ecabet sodico. |
AU2002338038A AU2002338038B2 (en) | 2001-09-27 | 2002-09-25 | Aqueous ecabet sodium solution preparation |
CA002460167A CA2460167A1 (en) | 2001-09-27 | 2002-09-25 | Aqueous ecabet sodium solution preparation |
NZ531937A NZ531937A (en) | 2001-09-27 | 2002-09-25 | Aqueous ecabet sodium solution preparation |
KR1020047004524A KR100606621B1 (ko) | 2001-09-27 | 2002-09-25 | 에카베트 나트륨 수성 용액 제제 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-296689 | 2001-09-27 | ||
JP2001296689 | 2001-09-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003028716A1 true WO2003028716A1 (en) | 2003-04-10 |
Family
ID=19117881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/009847 WO2003028716A1 (en) | 2001-09-27 | 2002-09-25 | Aqueous ecabet sodium solution preparation |
Country Status (11)
Country | Link |
---|---|
US (1) | US20040259905A1 (ja) |
EP (1) | EP1430892A4 (ja) |
JP (1) | JP4044902B2 (ja) |
KR (1) | KR100606621B1 (ja) |
CN (1) | CN1596108A (ja) |
AU (1) | AU2002338038B2 (ja) |
CA (1) | CA2460167A1 (ja) |
MX (1) | MXPA04002868A (ja) |
NZ (1) | NZ531937A (ja) |
TW (1) | TWI227137B (ja) |
WO (1) | WO2003028716A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009221199A (ja) * | 2008-03-14 | 2009-10-01 | Kwang Dong Pharmaceutical Co Ltd | 粒子の大きさが調節されたスルホデヒドロアビエチン酸を含有した苦味が低減された経口用の液状組成物 |
US8043662B2 (en) | 2005-08-22 | 2011-10-25 | Rohm And Haas Electronic Materials Llc | Aqueous solution for surface treatment of metal and method for preventing discoloration of metal surface |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109608357B (zh) * | 2019-01-08 | 2019-10-29 | 牡丹江医学院 | 一种治疗口腔炎的药物化合物和组合物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09136832A (ja) * | 1995-11-15 | 1997-05-27 | Tanabe Seiyaku Co Ltd | ドライアイおよびドライアイを原因とする疾患の予防・治療剤 |
WO2001034143A1 (fr) * | 1999-11-11 | 2001-05-17 | Tanabe Seiyaku Co., Ltd. | Agents de prevention ou de traitement de maladies inflammatoires de l'intestin |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3271037D1 (en) * | 1981-10-22 | 1986-06-12 | Tanabe Seiyaku Co | Salts of sulfodehydroabietic acid and treatment of gastro-intestinal diseases |
GB2107584A (en) * | 1981-10-22 | 1983-05-05 | Tanabe Seiyaku Co | Treatment of gastro-intestinal diseases |
-
2002
- 2002-09-25 EP EP02770213A patent/EP1430892A4/en not_active Withdrawn
- 2002-09-25 US US10/489,827 patent/US20040259905A1/en not_active Abandoned
- 2002-09-25 NZ NZ531937A patent/NZ531937A/en unknown
- 2002-09-25 JP JP2003532049A patent/JP4044902B2/ja not_active Expired - Fee Related
- 2002-09-25 AU AU2002338038A patent/AU2002338038B2/en not_active Ceased
- 2002-09-25 MX MXPA04002868A patent/MXPA04002868A/es unknown
- 2002-09-25 CN CNA028235991A patent/CN1596108A/zh active Pending
- 2002-09-25 KR KR1020047004524A patent/KR100606621B1/ko not_active IP Right Cessation
- 2002-09-25 TW TW091121961A patent/TWI227137B/zh not_active IP Right Cessation
- 2002-09-25 WO PCT/JP2002/009847 patent/WO2003028716A1/ja not_active Application Discontinuation
- 2002-09-25 CA CA002460167A patent/CA2460167A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09136832A (ja) * | 1995-11-15 | 1997-05-27 | Tanabe Seiyaku Co Ltd | ドライアイおよびドライアイを原因とする疾患の予防・治療剤 |
WO2001034143A1 (fr) * | 1999-11-11 | 2001-05-17 | Tanabe Seiyaku Co., Ltd. | Agents de prevention ou de traitement de maladies inflammatoires de l'intestin |
Non-Patent Citations (1)
Title |
---|
See also references of EP1430892A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8043662B2 (en) | 2005-08-22 | 2011-10-25 | Rohm And Haas Electronic Materials Llc | Aqueous solution for surface treatment of metal and method for preventing discoloration of metal surface |
JP2009221199A (ja) * | 2008-03-14 | 2009-10-01 | Kwang Dong Pharmaceutical Co Ltd | 粒子の大きさが調節されたスルホデヒドロアビエチン酸を含有した苦味が低減された経口用の液状組成物 |
Also Published As
Publication number | Publication date |
---|---|
AU2002338038B2 (en) | 2005-08-18 |
KR20040041631A (ko) | 2004-05-17 |
JP4044902B2 (ja) | 2008-02-06 |
EP1430892A1 (en) | 2004-06-23 |
CN1596108A (zh) | 2005-03-16 |
JPWO2003028716A1 (ja) | 2005-09-22 |
TWI227137B (en) | 2005-02-01 |
NZ531937A (en) | 2005-09-30 |
KR100606621B1 (ko) | 2006-07-31 |
EP1430892A4 (en) | 2006-03-01 |
CA2460167A1 (en) | 2003-04-10 |
MXPA04002868A (es) | 2004-07-15 |
US20040259905A1 (en) | 2004-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001236685B2 (en) | Preparation of aqueous clear solution dosage forms with bile acids | |
US7303768B2 (en) | Preparation of aqueous clear solution dosage forms with bile acids | |
RU2668882C2 (ru) | Жидкая фармацевтическая композиция | |
IL151132A (en) | Patridine compounds for the treatment of psoriasis | |
CN114555124A (zh) | 药物共晶盐制剂 | |
WO2001041757A1 (fr) | Composition pharmaceutique contenant de la cyclodextrine | |
WO2004018444A1 (fr) | Clathrates de phtalide butylique associe a de la cyclodextrine ou a ses derives, procede de preparation desdites compositions et leur utilisation | |
WO2016008546A1 (en) | Aqueous formulation comprising paracetamol and ibuprofen | |
WO2003028716A1 (en) | Aqueous ecabet sodium solution preparation | |
CN106943346B (zh) | 甲地高辛液体制剂、其制备方法及其用途 | |
CN102078611A (zh) | 含有聚维酮碘与环糊精包合糖皮质激素的局部外用组合物 | |
JPH02304026A (ja) | 腹腔洗浄液 | |
KR20120108218A (ko) | 위식도 역류질환 치료용 액상 타입 조성물 | |
WO1992017174A1 (en) | Process for preparing aqueous suspension | |
KR20120031051A (ko) | 경구 액제 | |
CN105828804A (zh) | 一种包含孟鲁司特或其药学上可接受的盐的液体制剂及其制备方法 | |
JP5019923B2 (ja) | プラノプロフェン含有医薬組成物 | |
KR101669556B1 (ko) | 몬테루카스트 또는 이의 약제학적으로 허용가능한 염의 경구투여용 액상제제 | |
JP7273257B1 (ja) | 医薬組成物 | |
WO2023100836A1 (ja) | 医薬組成物 | |
JP4860895B2 (ja) | リン酸プレドニゾロンナトリウム液体製剤 | |
JP2000219628A (ja) | アラトロフロキサシンの予め混合した注射用組成物 | |
WO2016082413A1 (zh) | 一种用于注射的右旋布洛芬药物组合物及其制备方法 | |
US20200246297A1 (en) | Liquid pharmaceutical formulations of tetraiodothyronine | |
AU2006203315B2 (en) | Preparation of aqueous clear solution dosage forms with bile acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2460167 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002338038 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002770213 Country of ref document: EP Ref document number: 10489827 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003532049 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 531937 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/002868 Country of ref document: MX Ref document number: 1020047004524 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028235991 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002770213 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 531937 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002338038 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 531937 Country of ref document: NZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002770213 Country of ref document: EP |